William Mack & Associates
REGN icon

William Mack & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

William Mack & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.28K Buy
+3
New +$2.27K ﹤0.01% 527

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

William Mack & Associates's REGN Position: Q3 2026 in Review

William Mack & Associates opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 3 shares worth $2.28K. The stake represents ﹤0.01% of the portfolio and ranks #527 among its holdings.

1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • William Mack & Associates held 3 shares of Regeneron Pharmaceuticals worth $2.28K as of Q3 2026.
  • Regeneron Pharmaceuticals was a new William Mack & Associates position in Q3 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #527 holding.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.